Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)
Completed
Calithera Biosciences, Inc
Phase 1/Phase 2
This study is an open-label Phase 1/ 2 evaluation of CB-839 in combination with nivolumab in
patients with clear cell renal cell carcinoma, melanoma, and non-small cell lung cancer.
Study of CB-839 in Combination w/ Paclitaxel in Patients of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC)
Completed
Calithera Biosciences, Inc
Phase 2
CX-839-007 is an open-label Phase 2 study of the combination of CB-839 with paclitaxel in
patients of African ancestry and non-African ancestry with advanced triple negative breast
cancer. Multiple single-arm cohorts will be enrolled in which 800 mg twice daily (BID) CB-839
will be administered in combination with the full approved dose of paclitaxel.
CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma
Completed
Calithera Biosciences, Inc
Phase 2
This clinical trial is a randomized Phase 2 evaluation of CB-839 (telaglenastat) in
combination with cabozantinib versus placebo with cabozantinib in patients with advanced or
metastatic Renal Cell Carcinoma with a clear cell component.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.